Drug intelligence / Profile preview

B1:SG + SHR1210

Development stage: Preclinical
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

B1:SG + SHR1210 is an experimental combination therapy consisting of two investigational agents. "B1:SG" is not a standard or widely recognized drug name in major pharmaceutical databases as of June 2025, and its identity cannot be confirmed from available sources. "SHR1210" is the code name for camrelizumab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), developed primarily for use as an immune checkpoint inhibitor in cancer immunotherapy. The combination likely aims to enhance antitumor efficacy by combining immune modulation with another agent (B1:SG), but the mechanism and details of B1:SG remain unclear due to lack of public data.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on B1:SG + SHR1210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B1:SG + SHR1210.

Explore the full profile